Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jun;26(6):1393-5.
doi: 10.1016/s0168-8278(97)80476-x.

Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns

P Honkoop  1 , H G Niesters, R A de Man, A D Osterhaus, S W Schalm
Affiliations

Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns

P Honkoop et al. J Hepatol. 1997 Jun.

Abstract

Background: Lamivudine is a non-toxic, potent inhibitor of hepatitis B virus replication. Recently, hepatitis B virus resistance to lamivudine has been described in patients using immunosuppressive drugs after liver transplantation.

Methods: From our cohort of 81 consecutive patients treated with lamivudine, we selected all immunocompetent patients who received lamivudine monotherapy for a period over 26 weeks (n=14).

Results: Lamivudine resistance with the characteristic mutation in the YMDD motif was observed in four patients (actuarial cumulative incidence: 39%). Two patterns of viral resistance were observed: incomplete response (n=2) and viral breakthrough (n=2).

Conclusions: The observed high frequency of lamivudine resistance may have implications for the concept of long-term virus-suppressive therapy of chronic hepatitis B by lamivudine monotherapy.

PubMed Disclaimer

Comment in

Publication types